期刊文献+

羟基喜树碱联合IL-2治疗恶性腹腔积液的疗效观察 被引量:3

Efficacy of combined HCPT with IL-2 in the treatment of malignant ascites of abdominal cavity
下载PDF
导出
摘要 目的:观察羟基喜树碱(HCPT)联合重组人白介素-2(IL-2)治疗恶性腹腔积液的疗效。方法:将24例恶性腹腔积液的患者置管放净腹水后,经导管注入NS40ml+HCTP20mg,NS40ml+IL-2100万单位,每周1~2次,观察总有效率及毒副反应。结果:24例患者总有效率为95.9%,腹痛4.1%,骨髓抑制发生率70.8%,均为Ⅰ°~Ⅱ°,发热8.3%,脱发100%,恶心75%,无呕吐,未见心电图及肝肾功能异常。结论:羟基喜树碱联合IL-2治疗恶性腹腔积液疗效好,副反应轻,值得推广。 Objective: Combine HCPT with IL -2 to cure malignant ascites of abdominal cavity and observe the curative effect. Methods: To put tubes into the abdomen of 24 patients with malignant ascites of abdominal cavity and absord the water completely,then inject NS40ml + HCPT 20 mg NS40ml + IL - 2 100u. Results: In the 24 patients,the total effetiverate was 95.9% ;bellyache 4.1% , the occurrence of marrow inhibiting rate was 70.8% , falling of air:100% ,nausea:75% ,liver and kidney function were normal. Conclusion: Combine HCPT with IL -2 to cure malignait precipitate of abdominal cavity can get a good curative effects.
出处 《现代肿瘤医学》 CAS 2007年第7期974-975,共2页 Journal of Modern Oncology
关键词 恶性腹腔积液 羟基喜树碱 重组人白介素-2 malignant ascites of abdominal cavity hydroxycamptuthecin recombine IL - 2
  • 相关文献

参考文献7

二级参考文献27

  • 1周振华,宋明志,王仁福.人天然白介素-2治疗恶性肿瘤的Ⅱ期临床观察[J].中国癌症杂志,1996,6(2):100-103. 被引量:4
  • 2沈靖南,潘启超.肿瘤药敏预测试验与临床化疗效应相关性的研究概况[J].癌症,1994,13(6):558-561. 被引量:8
  • 3[3]Walker-Renard PB,Vaughan LM,Sahn SA.Chemical pleurodesis for malignant pleural effusions[J].Ann Intern Med,1994,120:56~64. 被引量:1
  • 4Rowe PM. Camptothecins: new enthusiasm for an old drug.Lancet, 1995,347:892. 被引量:1
  • 5Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.The current status of camptothecin analogues as antitumor agents,J Natl Cancer Inst,1993,85:271. 被引量:1
  • 6Bleiberg H. Colorectal cancer: the challenge, Eut J Cancer,1996,32(A Suppl 5):S2. 被引量:1
  • 7Labianca R, Pessi A, Facendola G, et al. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer:a critical review of comparative studies. Eur J Cancer,1996,32(A Suppl5):S7. 被引量:1
  • 8Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11(irinotecan) ad a single agent in metastatic colorectal cancer.Eur J Cancer,1996,32(A Suppl3):S13. 被引量:1
  • 9Wiseman LR, Markham A. Irinotecan. A review of its pharma cological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs,1996,52:606. 被引量:1
  • 10Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer,1995,31(A Suppl 3):1283. 被引量:1

共引文献86

同被引文献11

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部